CorpWatch Exclusives
 | Medical Trial Data Activists Score Win Over Glaxo by Pratap Chatterjee, CorpWatch Blog February 7th, 2013 All data on completed medical experiments are to be made available to the general public by GlaxoSmithKline, the biggest UK pharmaceutical company. The announcement is a major win for the AllTrials campaign mounted by healthcare activists as well as researchers that has gathered widespread support. |
 | Grey Market Drugs: Profiting from Poorly Managed U.S. Health Care by Terry J. Allen, Special to CorpWatch January 22nd, 2012 Scalpers are doing a booming business in key medical drugs by taking advantage of U.S. patients and hospitals when they are desperate for supplies from the poorly regulated $46 billion global contract-manufacturing industry. |
 | Doctoring the Evidence: GlaxoSmithKline Pushes Depression Drug by Shelley Jofre, Special to Corp Watch July 30th, 2007 GlaxoSmithKline provides research funding to doctors who write favorable opinions of depression drugs for children, despite evidence from clinical trials that the medication can cause anger and even suicide. |
 | Merck's Murky Dealings: HPV Vaccine Lobby Backfires by Terry J. Allen, Special to CorpWatch March 7th, 2007 Merck's lobbying campaign for mandatory vaccination of school girls provided funding for a prominent women's non-profit. The ensuing uproar has created a backlash against the pharmaceutical giant. |
 | University, Inc. by Jennifer Borden, Special to CorpWatch April 11th, 2005 From research patents to high-stakes partnerships, Jennifer Washburn spent years researching the links between industry and the American University. In this exclusive interview with CorpWatch's Jennifer Borden, Washburn talks about what she found, why it matters and what you can do about it. |
 | Exporting Cures, Importing Misery by By Stan Cox, AlterNet January 19th, 2005 The Kazipally industrial area – once good farm country – now accounts for more than one-third of India's pharmaceutical industry, meaning skyrocketing rates of cancer, heart disease and birth defects for its residents. |
 | Biotechnology's Third Generation by Carmelo Ruiz-Marrero, Special to CorpWatch April 5th, 2002 From golden rice to anti-viral tomatoes, is the biotech industry's third generation good medicine or good marketing? And, activists ask, what are the environmental consequences? |
 | War Profiteering: Bayer, Anthrax and International Trade by Kavaljit Singh, Asia-Europe Dialogue Project November 5th, 2001 US officials have refused to bust Bayer's monopoly on anthrax drugs, even though generic drugs would save $millions. Bayer's patent was protected under the WTO. Now those rights are challenged. |
| Silence = Death: AIDS, Africa and Pharmaceuticals by Stephen Lewis, Toronto Globe and Mail January 26th, 2001 While 25 million Africans are living with AIDS, Northern pharmaceutical companies and governments are turning their back on the greatest tragedy of our time according to former deputy head of UNICEF. |